)
Edge10 Jul 2026
Inside Take-Two: The Grand Anticipation
The story of how Take-Two Interactive built the empire behind Grand Theft Auto, Red Dead Redemption, and one of gaming's largest mobile portfolios.
Q32 Bio
Q32 Bio (QTTB) investor relations material
Q32 Bio Registration filing summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Registration filing summary17 Jul, 2026
Company overview and business model
Clinical-stage biotechnology company developing therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases.
Lead candidate bempikibart (ADX-914) is a monoclonal antibody targeting interleukin-7 receptor alpha, with Phase 2a trials completed for AA and atopic dermatitis.
Corporate restructuring in February 2025 to focus on bempikibart for AA; sold ADX-097 asset to Akebia Therapeutics in November 2025.
Retains rights to early-stage complement inhibitor platform assets and is evaluating strategic options for these programs.
Financial performance and metrics
Classified as a smaller reporting company, eligible for scaled disclosure requirements due to market value and revenue thresholds.
No cash dividends declared or paid; intends to retain earnings for business development and expansion.
Use of proceeds and capital allocation
Will not receive proceeds from the resale of shares by selling stockholders; may receive nominal proceeds from exercise of pre-funded warrants.
Proceeds from pre-funded warrants, if exercised for cash, will be used for general corporate purposes.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Q32 Bio
- Bempikibart showed strong efficacy, safety, and durability in severe alopecia areata at 36 weeks.QTTB
Study result13 Jul 2026 - Registering up to $300M in securities to advance lead autoimmune therapy and fund operations.QTTBRegistration filing25 Jun 2026
- All proposals, including director elections and audit firm ratification, were approved.QTTBAGM 202612 Jun 2026
- Q1 2026 net loss narrowed to $7.6M; cash runway into 2028 after equity raises and asset sale.QTTBQ1 20265 May 2026
- Lead asset bempikibart delivers durable AA responses and strong safety, with pivotal data due mid-2026.QTTBCompany presentation5 May 2026
- Virtual annual meeting to vote on directors, auditor, and executive pay, with strong governance.QTTBProxy filing30 Apr 2026
- Election of directors, auditor ratification, and say-on-pay up for shareholder vote.QTTBProxy filing30 Apr 2026
- Lead asset bempikibart targets unmet needs in alopecia areata, with pivotal data due mid-year.QTTB25th Annual Needham Virtual Healthcare Conference15 Apr 2026
- Bempikibart delivers durable, safe hair regrowth in AA, with pivotal data expected mid-2026.QTTBCompany presentation10 Mar 2026
Next Q32 Bio earnings date
Q2 20266 Aug, 2026
Q32 Bio
Next Q32 Bio earnings date
Q2 20266 Aug, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage